文献速递传染病防控与疫情报告免疫规划环境卫生

当前与未来的霍乱疫苗

Current and future cholera vaccines.
PubMed 文献 · Vaccine · 2019-12-24

霍乱仍是全球主要公共卫生问题,与安全用水和卫生设施不足相关。口服霍乱疫苗(OCV)被推荐与WASH一起用于霍乱流行国家和疫情风险地区。新一代OCV安全且对较大儿童和成人有良好保护,但对5岁以下儿童保护有限;孕妇中安全。全球需求因WHO推荐、疫情驱动、廉价易用疫苗、大规模接种可行性及Gavi承担费用而增长。2013年建立全球OCV储备,三种WHO预认证疫苗为Dukoral®、Shanchol™、Euvichol®(及Euvichol® Plus),后两者纳入储备。

要点

  • OCV被推荐与WASH一起用于霍乱流行国家和疫情风险地区。
  • 新一代OCV对较大儿童和成人保护良好,对5岁以下儿童保护有限。
  • OCV在孕妇中安全,支持在流行国家孕妇中使用。

核心结论

  • OCV是霍乱防控的附加公共卫生工具,需与WASH结合使用。
  • 当前疫苗需延长保护持续时间,并改进对年幼儿童的免疫应答。
  • 单剂次接种方案更具成本效果且更易实施,近期研究聚焦于基因减毒株用于单剂次疫苗。

研究设计与样本

  • 综述类文章,检索范围未报告。

主要发现

  • 新一代OCV对较大儿童和成人提供良好保护,对5岁以下儿童保护有限。
  • OCV在孕妇中安全,支持在霍乱流行国家孕妇中使用。
  • 直接疫苗保护与疫苗群体免疫效应结合使OCV高度成本效果。
  • 全球OCV需求因WHO推荐、疫情和爆发驱动、廉价易用疫苗可得性、大规模接种可行性、对脆弱人群保护示范及Gavi承担费用而增长。

关键数值与推荐

  • 三种WHO预认证疫苗为Dukoral®、Shanchol™、Euvichol®(及Euvichol® Plus),后两者纳入全球OCV储备。
  • 全球OCV储备于2013年在全球疫苗免疫联盟支持下建立。

临床怎么用

  • OCV被推荐作为附加公共卫生工具与WASH一起用于霍乱流行国家和疫情风险地区。
  • OCV可在霍乱流行国家孕妇中使用。
  • 单剂次接种方案更具成本效果且更易实施。

局限性

  • 对当前疫苗延长保护持续时间的知识需发展。
  • 疫苗需改进以对年幼儿童产生更好免疫应答。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cholera remains a major global public health problem that is primarily linked to insufficient access to safe water and proper sanitation. Oral Cholera Vaccine (OCV) has been recommended as an additional public health tool along with WASH in cholera endemic countries and in areas at risk for outbreaks. The new generation OCV is safe and offers good protection in older children and adults while limited protection in younger children less than five years of age has been observed. The combination of direct vaccine protection and vaccine herd immunity effects makes OCV highly cost-effective and, therefore, attractive for use in developing countries. Additionally, in recent studies OCV was safe in pregnant women, supporting its use in pregnant women in cholera endemic countries. However, knowledge need to be developed for current vaccines for their prolonged duration of protection and vaccines need improvements for better immune response in younger children. A single dose vaccination regimen would be more cost-effective and easier to deliver. Recent approaches have focused on designing genetically attenuated cholera strains for use in single-dose cholera vaccines. The global demand for OCV has been boosted by the WHO recommendation to use OCV and is driven largely by epidemics and outbreaks and has been increasing due to the availability of cheaper easy-to-use vaccines, feasibility of mass OCV vaccination campaigns, demonstration of protection to underserved population in precarious situations, and vaccine costs being borne by Gavi (Vaccine Alliance). For rapid access in emergency and equitable distribution of OCV in cholera-endemic low-income countries, a global OCV stockpile was established in 2013 with support from the Global Alliance for Vaccines and Immunization. The three WHO-prequalified vaccines are Dukoral®, Shanchol™, Euvichol® (and Euvichol® Plus presentation), the latter two being included in the stockpile.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Shaikh H, Lynch J, Kim J, et al. Current and future cholera vaccines. Vaccine. 2019. PMID: 31879125. doi:10.1016/j.vaccine.2019.12.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。